Research programme: CD8+ T cell cis-targeted STAT3 cytokine immunotherapies - Asher Biotherapeutics
Latest Information Update: 21 Dec 2021
At a glance
- Originator Asher Biotherapeutics
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD8 positive T lymphocyte stimulants; Cytokine stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer